151 related articles for article (PubMed ID: 38307584)
1. Integration of the Molecular Classification of Endometrial Carcinoma to Select Patients for Fertility Sparing Strategies.
Bani MA; Maulard A; Morice P; Chargari C; Genestie C
Anticancer Res; 2024 Feb; 44(2):445-452. PubMed ID: 38307584
[TBL] [Abstract][Full Text] [Related]
2. Application of the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) to patients conservatively treated: Outcomes from an institutional series.
Falcone F; Normanno N; Losito NS; Scognamiglio G; Esposito Abate R; Chicchinelli N; Casella G; Laurelli G; Scaffa C; Greggi S
Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():220-225. PubMed ID: 31326637
[TBL] [Abstract][Full Text] [Related]
3. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
Gong Q; Chen X; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
[TBL] [Abstract][Full Text] [Related]
4. [Fertility-preserving treatment outcomes in endometrial cancer and atypical hyperplasia patients with different molecular profiles].
Shao WY; Dong YT; Lyu QY; Liao JB; Xue Y; Chen XJ
Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):742-754. PubMed ID: 37849255
[No Abstract] [Full Text] [Related]
5. Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol.
Talhouk A; Jamieson A; Crosbie EJ; Taylor A; Chiu D; Leung S; Grube M; Kommoss S; Gilks CB; McAlpine JN; Singh N
Int J Gynecol Pathol; 2023 Jul; 42(4):353-363. PubMed ID: 36731023
[TBL] [Abstract][Full Text] [Related]
6. Updates on Conservative Management of Endometrial Cancer.
Corzo C; Barrientos Santillan N; Westin SN; Ramirez PT
J Minim Invasive Gynecol; 2018 Feb; 25(2):308-313. PubMed ID: 28782618
[TBL] [Abstract][Full Text] [Related]
7. Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer.
Chae SH; Shim SH; Lee SJ; Lee JY; Kim SN; Kang SB
Int J Gynecol Cancer; 2019 Jan; 29(1):77-85. PubMed ID: 30640687
[TBL] [Abstract][Full Text] [Related]
8. Application of molecular classification to guiding fertility-sparing therapy for patients with endometrial cancer or endometrial intraepithelial neoplasia.
Zhang X; Chen D; Zhao X; Wang C; He Y; Chen Y; Wang J; Shen D
Pathol Res Pract; 2023 Jan; 241():154278. PubMed ID: 36580798
[TBL] [Abstract][Full Text] [Related]
9. Fertility-sparing treatment for intramucous, moderately differentiated, endometrioid endometrial cancer: a Gynecologic Cancer Inter-Group (GCIG) study.
Falcone F; Leone Roberti Maggiore U; Di Donato V; Perrone AM; Frigerio L; Bifulco G; Polterauer S; Casadio P; Cormio G; Masciullo V; Malzoni M; Greggi S
J Gynecol Oncol; 2020 Sep; 31(5):e74. PubMed ID: 32808500
[TBL] [Abstract][Full Text] [Related]
10. [Significance of molecular classification in fertility-sparing treatment of endometrial carcinoma and atypical endometrial hyperplasia].
Wang YQ; Kang N; Li LW; Wang ZQ; Zhou R; Shen DH; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):692-700. PubMed ID: 36177581
[No Abstract] [Full Text] [Related]
11. Molecular and pathologic data to guide selection of patients with endometrioid endometrial cancer for ovarian preservation.
Manning-Geist BL; Rios-Doria E; Liu YL; Ellenson LH; Zhou QC; Iasonos A; Leitao MM; Abu-Rustum NR; Weigelt B; Mueller JJ
Int J Gynecol Cancer; 2024 May; 34(5):697-704. PubMed ID: 38508587
[TBL] [Abstract][Full Text] [Related]
12. Biomolecular and Genetic Prognostic Factors That Can Facilitate Fertility-Sparing Treatment (FST) Decision Making in Early Stage Endometrial Cancer (ES-EC): A Systematic Review.
Tanos P; Dimitriou S; Gullo G; Tanos V
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269800
[TBL] [Abstract][Full Text] [Related]
13. Fertility-Sparing Approach in Patients with Endometrioid Endometrial Cancer Grade 2 Stage IA (FIGO): A Qualitative Systematic Review.
Giampaolino P; Cafasso V; Boccia D; Ascione M; Mercorio A; Viciglione F; Palumbo M; Serafino P; Buonfantino C; De Angelis MC; Verrazzo P; Grasso G; Gullo G; Bifulco G; Della Corte L
Biomed Res Int; 2022; 2022():4070368. PubMed ID: 36203482
[TBL] [Abstract][Full Text] [Related]
14. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
Bosse T; Nout RA; McAlpine JN; McConechy MK; Britton H; Hussein YR; Gonzalez C; Ganesan R; Steele JC; Harrison BT; Oliva E; Vidal A; Matias-Guiu X; Abu-Rustum NR; Levine DA; Gilks CB; Soslow RA
Am J Surg Pathol; 2018 May; 42(5):561-568. PubMed ID: 29505428
[TBL] [Abstract][Full Text] [Related]
15. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
[TBL] [Abstract][Full Text] [Related]
16. The pregnancy and oncology outcome of fertility-sparing management for synchronous primary neoplasm of endometrium and ovary.
Gama Q; Luo S; Wu P; Wang L; Liu S; Zhang H; Sun L; Wang Y; Yu M; Chen X; Shan W; Luo X
J Ovarian Res; 2023 Dec; 16(1):235. PubMed ID: 38062462
[TBL] [Abstract][Full Text] [Related]
17. [Fertility-sparing management of endometrial cancer and atypical hyperplasia].
Gonthier C; Trefoux-Bourdet A; Luton D; Koskas M
Gynecol Obstet Fertil Senol; 2017 Feb; 45(2):112-118. PubMed ID: 28368791
[TBL] [Abstract][Full Text] [Related]
18. Incorporation of molecular characteristics into endometrial cancer management.
Vermij L; Smit V; Nout R; Bosse T
Histopathology; 2020 Jan; 76(1):52-63. PubMed ID: 31846532
[TBL] [Abstract][Full Text] [Related]
19. Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer.
Chung YS; Woo HY; Lee JY; Park E; Nam EJ; Kim S; Kim SW; Kim YT
Am J Obstet Gynecol; 2021 Apr; 224(4):370.e1-370.e13. PubMed ID: 33039397
[TBL] [Abstract][Full Text] [Related]
20. Optimal duration of fertility-sparing hormonal treatment for early-stage endometrioid endometrial cancer.
Shim SH; Chae SH; So KA; Lee SJ; Lee JY; Kim TJ; Han ES; Kang SB
Gynecol Oncol; 2021 Jun; 161(3):810-816. PubMed ID: 33875233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
